Cyclobutane-Based Peptides Selectively Target Leishmania Parasites While Sparing Human Cells
Novel cyclobutane-containing peptides selectively targeted and killed Leishmania parasites while showing no toxicity to human cells, with drug conjugates active at 1 µM.
Quick Facts
What This Study Found
Two series of hybrid gamma/gamma-peptides (gamma-CC and gamma-CT) were designed using a chiral cyclobutane amino acid alternating with proline derivatives. Key findings:
Selectivity: both peptide series showed no cytotoxicity to human HeLa cells and only moderate uptake by these cells. In contrast, both 14-mer versions were microbicidal against Leishmania at concentrations above 25 micromolar, with significant intracellular accumulation in the parasite.
Drug delivery: when conjugated to fluorescent doxorubicin (Dox), the peptides showed toxicity to Leishmania above 1 micromolar, while free Dox at the same concentration was not toxic. Intracellular accumulation was 2.5 times higher than with a Dox-TAT conjugate (TAT being the standard cell-penetrating peptide).
Structural insight: computational calculations showed the drug-peptide conjugates fold to bury the Dox moiety inside a cavity while exposing positively charged groups to solvent. This improves Dox solubility and membrane translocation.
Key Numbers
Non-toxic to HeLa; killing >25µM; Dox conjugate >1µM; 2.5x vs TAT accumulation; 14-mer optimal
How They Did This
Peptide chemistry and parasitology study. Hybrid gamma-peptides were synthesized and tested for cytotoxicity (HeLa cells), parasite killing (Leishmania), and intracellular accumulation. Doxorubicin conjugates were prepared and compared to free Dox and Dox-TAT. Conformational analysis by circular dichroism and molecular dynamics simulations.
Why This Research Matters
Leishmaniasis affects 12 million people and kills 20,000-30,000 annually. Current drugs are toxic and losing effectiveness. A delivery system that selectively targets the parasite while sparing human cells could transform treatment. The 2.5-fold improvement over TAT peptide delivery is significant.
The Bigger Picture
Leishmaniasis affects 12 million people and kills 20,000–30,000 annually. Current drugs are toxic and losing effectiveness. A delivery system that selectively targets the parasite while sparing human cells could transform treatment of this neglected tropical disease.
What This Study Doesn't Tell Us
Tested only in cell culture, not in animal infection models. The selectivity mechanism (why parasites take up the peptide more than human cells) is not fully explained. Only one drug (doxorubicin) was tested as cargo. The 25 micromolar killing concentration for the peptide alone is relatively high. Long-term stability and in vivo biodistribution are unknown.
Questions This Raises
- ?Why do parasites accumulate the peptide more than human cells?
- ?Would this work with other anti-parasitic drugs besides doxorubicin?
- ?Can these peptides be manufactured affordably for low-income settings?
Trust & Context
- Key Stat:
- 2.5× selectivity these peptides accumulate inside Leishmania parasites 2.5 times more than the well-known TAT cell-penetrating peptide
- Evidence Grade:
- Preliminary evidence from in vitro studies only. Parasite selectivity is promising but animal infection models are needed.
- Study Age:
- Published in 2020. Peptide-based anti-parasitic strategies continue to be developed for neglected tropical diseases.
- Original Title:
- Chiral Cyclobutane-Containing Cell-Penetrating Peptides as Selective Vectors for Anti-Leishmania Drug Delivery Systems.
- Published In:
- International journal of molecular sciences, 21(20) (2020)
- Authors:
- Illa, Ona, Olivares, José-Antonio, Gaztelumendi, Nerea, Martínez-Castro, Laura, Ospina, Jimena, Abengozar, María-Ángeles, Sciortino, Giuseppe, Maréchal, Jean-Didier, Nogués, Carme, Royo, Míriam, Rivas, Luis, Ortuño, Rosa M
- Database ID:
- RPEP-04872
Evidence Hierarchy
Frequently Asked Questions
Why is Leishmania so hard to treat?
Current drugs are toxic, expensive, and increasingly ineffective due to parasite resistance. A delivery system that puts drugs directly inside parasites while avoiding human cells could make treatment safer and more effective.
How do these peptides tell parasites from human cells?
The exact mechanism is not fully understood, but the cyclobutane peptides accumulate inside parasites much more than in human cells. This selectivity means the drug cargo is concentrated where it is needed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04872APA
Illa, Ona; Olivares, José-Antonio; Gaztelumendi, Nerea; Martínez-Castro, Laura; Ospina, Jimena; Abengozar, María-Ángeles; Sciortino, Giuseppe; Maréchal, Jean-Didier; Nogués, Carme; Royo, Míriam; Rivas, Luis; Ortuño, Rosa M. (2020). Chiral Cyclobutane-Containing Cell-Penetrating Peptides as Selective Vectors for Anti-Leishmania Drug Delivery Systems.. International journal of molecular sciences, 21(20). https://doi.org/10.3390/ijms21207502
MLA
Illa, Ona, et al. "Chiral Cyclobutane-Containing Cell-Penetrating Peptides as Selective Vectors for Anti-Leishmania Drug Delivery Systems.." International journal of molecular sciences, 2020. https://doi.org/10.3390/ijms21207502
RethinkPeptides
RethinkPeptides Research Database. "Chiral Cyclobutane-Containing Cell-Penetrating Peptides as S..." RPEP-04872. Retrieved from https://rethinkpeptides.com/research/illa-2020-chiral-cyclobutanecontaining-cellpenetrating-peptides
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.